Literature DB >> 19265475

Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.

Stephanie Jones1, Peter D Peng, Shicheng Yang, Cary Hsu, Cyrille J Cohen, Yangbing Zhao, John Abad, Zhili Zheng, Steven A Rosenberg, Richard A Morgan.   

Abstract

Lentiviral vectors containing promoters of distinct origins, that is, strong viral promoters (cytomegalovirus [CMV] and murine stem cell virus [MSCV]), a cellular promoter (phosphoglycerate kinase [PGK]), and two composite promoters (CAG [a composite promoter sequence comprised of the CMV enhancer and portions of the chicken beta-actin promoter and the rabbit beta-globin gene] and SV40/CD43), were used to evaluate green fluorescent protein (GFP) reporter gene expression in human primary peripheral blood lymphocytes (PBLs) and tumor-infiltrating lymphocytes (TILs). In PBLs, vectors containing the MSCV promoter were found to be optimal for expression in both minimally stimulated and highly activated lymphocytes. The stability of gene expression was monitored for up to 7 weeks in culture and the MSCV promoter-containing vector was found to be comparable to the cellular PGK promoter-containing vector. The MSCV promoter-containing lentiviral vector was also the most active in transduced TILs and these cells retained biological activity as measured by antimelanoma antigen reactivity. Using the knowledge gained in comparing individual promoters, a series of two-gene-containing lentiviral vectors was constructed in an attempt to produce the alpha and beta chains of antitumor antigen T cell receptors (TCRs). Dual-promoter or internal ribosome entry site (IRES)-containing vector designs were evaluated and found to be unable to produce both chains of the TCR in amounts that led to significant biological activity. In contrast, if the alpha and beta chains were linked by a 2A ribosomal skip peptide, both proper TCR chain pairing and biologically activity were observed. This paper emphasizes the need to optimize both promoter function and protein synthesis in constructs that require stoichiometric production of multiple protein subunits.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265475      PMCID: PMC2828626          DOI: 10.1089/hum.2008.048

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  42 in total

1.  Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression.

Authors:  Gregory Lizée; Joeri L Aerts; Monica I Gonzales; Nachimuthu Chinnasamy; Richard A Morgan; Suzanne L Topalian
Journal:  Hum Gene Ther       Date:  2003-04-10       Impact factor: 5.695

2.  High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.

Authors:  Z Gao; J Golob; V M Tanavde; C I Civin; R G Hawley; L Cheng
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

3.  Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

Authors:  Xiaobing Yu; Xiangcan Zhan; Jenice D'Costa; Vivek M Tanavde; Zhaohui Ye; Tien Peng; Matthew T Malehorn; Xiaoming Yang; Curt I Civin; Linzhao Cheng
Journal:  Mol Ther       Date:  2003-06       Impact factor: 11.454

4.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors:  Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

Review 6.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

7.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Eric Y Chen; Brent L Wood; Harvey A Greisman; Xiaojun Qian; Scott E James; Andrew Raubitschek; Stephen J Forman; Ajay K Gopal; John M Pagel; Catherine G Lindgren; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2008-05-28       Impact factor: 22.113

Review 8.  Targeting tumours with genetically enhanced T lymphocytes.

Authors:  Michel Sadelain; Isabelle Rivière; Renier Brentjens
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

9.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.

Authors:  Alessandro Aiuti; Sergio Vai; Alessandra Mortellaro; Giulia Casorati; Francesca Ficara; Grazia Andolfi; Giuliana Ferrari; Antonella Tabucchi; Filippo Carlucci; Hans D Ochs; Luigi D Notarangelo; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

10.  Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence.

Authors:  Simona Cavalieri; Sabrina Cazzaniga; Massimo Geuna; Zulma Magnani; Claudio Bordignon; Luigi Naldini; Chiara Bonini
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

View more
  35 in total

1.  T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

Authors:  Aude G Chapuis; Daniel N Egan; Merav Bar; Thomas M Schmitt; Megan S McAfee; Kelly G Paulson; Valentin Voillet; Raphael Gottardo; Gunnar B Ragnarsson; Marie Bleakley; Cecilia C Yeung; Petri Muhlhauser; Hieu N Nguyen; Lara A Kropp; Luca Castelli; Felecia Wagener; Daniel Hunter; Marcus Lindberg; Kristen Cohen; Aaron Seese; M Juliana McElrath; Natalie Duerkopp; Ted A Gooley; Philip D Greenberg
Journal:  Nat Med       Date:  2019-06-24       Impact factor: 53.440

2.  Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Authors:  Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew D M Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

3.  Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.

Authors:  Anna Pasetto; Alena Gros; Paul F Robbins; Drew C Deniger; Todd D Prickett; Rodrigo Matus-Nicodemos; Daniel C Douek; Bryan Howie; Harlan Robins; Maria R Parkhurst; Jared Gartner; Katarzyna Trebska-McGowan; Jessica S Crystal; Steven A Rosenberg
Journal:  Cancer Immunol Res       Date:  2016-06-28       Impact factor: 11.151

4.  Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells.

Authors:  Olivier Humbert; Don W Gisch; Martin E Wohlfahrt; Amie B Adams; Phil D Greenberg; Tom M Schmitt; Grant D Trobridge; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2016-04-08       Impact factor: 11.454

5.  Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations.

Authors:  Joshua R Veatch; Brenda L Jesernig; Julia Kargl; Matthew Fitzgibbon; Sylvia M Lee; Christina Baik; Renato Martins; A McGarry Houghton; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2019-05-01       Impact factor: 11.151

6.  T Cell Receptor Engineered Lymphocytes for Cancer Therapy.

Authors:  Meagan R Rollins; Ellen J Spartz; Ingunn M Stromnes
Journal:  Curr Protoc Immunol       Date:  2020-06

7.  A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.

Authors:  Shicheng Yang; Mark E Dudley; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2010 Jul-Aug       Impact factor: 4.456

8.  piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Authors:  Pallavi V Raja Manuri; Matthew H Wilson; Sourindra N Maiti; Tiejuan Mi; Harjeet Singh; Simon Olivares; Margaret J Dawson; Helen Huls; Dean A Lee; Pulivarthi H Rao; Joseph M Kaminski; Yozo Nakazawa; Stephen Gottschalk; Partow Kebriaei; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 9.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

10.  Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.

Authors:  Shicheng Yang; Yun Ji; Luca Gattinoni; Ling Zhang; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Immunol Immunother       Date:  2012-12-04       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.